Shao Tingguo, Zhang Yuqing, Tang Rubo, Zhang Hai, Wang Quanzheng, Yang Ying, Liu Tongxiang
Department of Cardiology, Dongcheng Branch, Shouguang People's Hospital, Weifang, Shandong 262704, P.R. China.
Department of Vasculocardiology, Shouguang People's Hospital, Weifang, Shandong 262700, P.R. China.
Exp Ther Med. 2018 Nov;16(5):4162-4166. doi: 10.3892/etm.2018.6672. Epub 2018 Aug 31.
Effects of milrinone on serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), cystatin C (Cys-C) and cardiac functions of patients with chronic heart failure were analyzed to investigate the value of milrinone in chronic heart failure. A total of 70 patients diagnosed with chronic heart failure were selected and randomly divided into treatment group (n=35) and control group (n=35). All patients were treated with conventional anti-heart failure therapy, and patients in the treatment group received milrinone on the basis of conventional therapy. The general data of patients, such as age, sex and course of chronic heart failure, were collected; the levels of serum IL-6, TNF-α and Cys-C before and after treatment were compared between the groups, and the cardiac function indexes were also compared, including cardiac output (CO), stroke volume (SV), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVDd), left ventricular end-systolic diameter (LVSd) and brain natriuretic peptide (BNP) level. Besides, the curative effects and adverse reactions in the two groups were recorded. The results revealed that serum IL-6, TNF-α and Cys-C levels had no significant difference between the two groups before treatment; however, the curative effect in the treatment group was significantly superior to that in control group (p<0.05); after treatment, CO, SV and LVEF in both groups were obviously increased, but LVDd, LVSd and BNP levels were obviously decreased; the curative effect in the treatment group was significantly superior to that in control group (p<0.05); heart rate in both groups was obviously decreased after treatment (p<0.05); the total effective rate in the treatment group was significantly higher than that in control group after treatment (p<0.05). In conclusion, based on the conventional anti-heart failure therapy, the application of milrinone can reduce the serum IL-6, TNF-α and Cys-C levels and improve the cardiac functions of patients effectively.
分析米力农对慢性心力衰竭患者血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、胱抑素C(Cys-C)及心功能的影响,以探讨米力农在慢性心力衰竭中的应用价值。选取70例确诊为慢性心力衰竭的患者,随机分为治疗组(n = 35)和对照组(n = 35)。所有患者均接受常规抗心力衰竭治疗,治疗组患者在常规治疗基础上加用米力农。收集患者的一般资料,如年龄、性别及慢性心力衰竭病程;比较两组治疗前后血清IL-6、TNF-α及Cys-C水平,同时比较心功能指标,包括心输出量(CO)、每搏输出量(SV)、左心室射血分数(LVEF)、左心室舒张末期内径(LVDd)、左心室收缩末期内径(LVSd)及脑钠肽(BNP)水平。此外,记录两组的疗效及不良反应。结果显示,治疗前两组血清IL-6、TNF-α及Cys-C水平无显著差异;然而,治疗组疗效明显优于对照组(p < 0.05);治疗后,两组的CO、SV及LVEF均明显升高,但LVDd、LVSd及BNP水平明显降低;治疗组疗效明显优于对照组(p < 0.05);两组治疗后心率均明显降低(p < 0.05);治疗后治疗组总有效率明显高于对照组(p < 0.05)。综上所述,在常规抗心力衰竭治疗基础上,应用米力农可有效降低患者血清IL-6、TNF-α及Cys-C水平,改善心功能。